November 28, 2016 - By Marguerite Chambers
Penny stock shareholders are becoming inquisitive about ROCK CREEK PHARMACEUTICALS INCORPORATED (OTCMKTS:RCPIQ), following the fact that the share price has moved $0.0004, reaching the $0.0014 price level in a recent trade.
A big benefit of investing in small-cap shares is that there is a prospect to outpace the institutional investors. In addition, mutual funds have limits controlling their power to purchase large lots of any one firm’s outstanding shares.
It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, ROCK CREEK PHARMACEUTICALS INCORPORATED’s stock was big mover. According to the short interest report published recently, (RCPIQ) had 51,600 shorted shares for 0 days to cover. The prior short interest was 1,600 for a $3125.00 change. The 52-Week High and Low are noted here. -99.87% (High), Infinity, (Low). The stock had 1.91M average volume.
Is stock price of ROCK CREEK PHARMACEUTICALS INCORPORATED Set to Getaway to Their Potential? Register for Our Newsletter and Know the Inside Scoop!
As seen in stock market, the first point in investing in penny shares is to earn money. A popular trait of penny shares is that they move quickly and are extremely volatile. Penny shares are mainly stocks of small cap firms that can be open to change in industry conditions and stock market sentiments. Though penny shares are generally stated to be dicey, a trader can make massive amount of money in a short period of time, as against bigger, so-named ‘blue chip’ shares and mutual funds, which need a long-term plan.
Needless to state, investing in penny stock is not a right choice for the risk-averse, and only non-essential disposable income or ‘play money’ should be put in penny stocks. In no way are these stocks termed as the conservative investments and traders who play them are willing to take risks with invested capital. Penny stock shareholders must be prepared to put on stake their entire investment. Penny stocks trade fast in directions, recording massive downticks or upticks in few hours.
Receive Breaking Updates by Enrolling to our Newsletter! Hit on the Bar Below and Explore About Stocks that are Set to Make a Run!
Anticipated penny stock investors should learn and gain knowledge of the penny stock market. They must conduct intense research of a firm they might want to invest their money into. Learning can start by enrolling to a penny stock newsletter which offers informative penny stock recommendations. Gathering data as much as you can that is related to the penny stock world is tremendously vital if you want to earn money in trading. It is highly suggested that you enter into the market with a small amount of capital to lessen the risk if you incur a loss.
Disclaimer: The information, views, and opinions expressed in this publication are those of the writers and do not necessarily shows the position or official policy of any company financial professionals, analysts or stakeholders. Examples of assessment performed within this publication are just examples. They should not be used to make financial decisions or stock portfolio as they are based merely on open source and limited information. Assumptions taken within the study are not indicative of the position of any financial professionals or analysts.
More notable recent Rock Creek Pharmaceuticals Inc (OTCMKTS:RCPIQ) news were published by: Prnewswire.com which released: “Rock Creek Pharmaceuticals Announces Japanese, European and U.S. Patent …” on May 05, 2016, also Bizjournals.com with their article: “Bay area biopharma firm files for bankruptcy” published on September 28, 2016, Prnewswire.com published: “Rock Creek Pharmaceuticals Announces Inhibition of STAT 3 Activation, A Key …” on February 03, 2016. More interesting news about Rock Creek Pharmaceuticals Inc (OTCMKTS:RCPIQ) were released by: Prnewswire.com and their article: “Rock Creek Pharmaceuticals Announces Interim Amendments to Convertible Notes …” published on July 08, 2016 as well as Prnewswire.com‘s news article titled: “Rock Creek Pharmaceuticals Announces $3.7 Million Registered Direct Offering” with publication date: June 17, 2015.
Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The company has a market cap of $238,616. The Firm is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. It currently has negative earnings. The Company’s activities are focused on its lead compound, anatabine citrate .
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.